Show simple item record

dc.contributor.authorObasaju, Coleman K
dc.contributor.authorCowan, Richard A
dc.contributor.authorWilkinson, Peter M
dc.date.accessioned2010-05-25T11:05:08Z
dc.date.available2010-05-25T11:05:08Z
dc.date.issued1993
dc.identifier.citationRecurrent cervical cancer treated with cisplatin and methotrexate. 1993, 5 (4):203-6 Clin Oncolen
dc.identifier.issn0936-6555
dc.identifier.pmid8398915
dc.identifier.doi10.1016/S0936-6555(05)80228-6
dc.identifier.urihttp://hdl.handle.net/10541/99798
dc.description.abstractA combination of cisplatin (80 mg/m2) and methotrexate (200 mg bolus and 400 mg as a 12-hour infusion) was given to 40 patients who developed local recurrence of cervical cancer after radiotherapy. A maximum of six courses was given at monthly intervals. Twenty-five of the forty (63%) evaluable patients responded, of which 4 (10%) responded completely. A symptomatic response, with reduction of pain, leg oedema, vaginal discharge and breathlessness was seen in 27 (68%) of patients. The median survival of all patients was 11 months. Toxicity was moderate; WHO grade 1 or greater was observed in 83% for nausea and vomiting, 67% for myelosuppression and 47% for mucositis. This combination chemotherapy is active in the treatment of recurrent cervical cancer and a modification of this regimen is currently being assessed as neo-adjuvant therapy in patients with Stage IIB-IVA cervical cancer.
dc.language.isoenen
dc.subjectCancer Recurrenceen
dc.subject.meshAdenocarcinoma
dc.subject.meshAdult
dc.subject.meshAntineoplastic Combined Chemotherapy Protocols
dc.subject.meshCarcinoma, Adenosquamous
dc.subject.meshCarcinoma, Squamous Cell
dc.subject.meshChemotherapy, Adjuvant
dc.subject.meshCisplatin
dc.subject.meshDrug Administration Schedule
dc.subject.meshFemale
dc.subject.meshHumans
dc.subject.meshMethotrexate
dc.subject.meshMiddle Aged
dc.subject.meshNeoplasm Recurrence, Local
dc.subject.meshSurvival Rate
dc.subject.meshUterine Cervical Neoplasms
dc.titleRecurrent cervical cancer treated with cisplatin and methotrexate.en
dc.typeArticleen
dc.contributor.departmentChristie Hospital NHS Trust, Withington, Manchester, UK.en
dc.identifier.journalClinical Oncologyen
html.description.abstractA combination of cisplatin (80 mg/m2) and methotrexate (200 mg bolus and 400 mg as a 12-hour infusion) was given to 40 patients who developed local recurrence of cervical cancer after radiotherapy. A maximum of six courses was given at monthly intervals. Twenty-five of the forty (63%) evaluable patients responded, of which 4 (10%) responded completely. A symptomatic response, with reduction of pain, leg oedema, vaginal discharge and breathlessness was seen in 27 (68%) of patients. The median survival of all patients was 11 months. Toxicity was moderate; WHO grade 1 or greater was observed in 83% for nausea and vomiting, 67% for myelosuppression and 47% for mucositis. This combination chemotherapy is active in the treatment of recurrent cervical cancer and a modification of this regimen is currently being assessed as neo-adjuvant therapy in patients with Stage IIB-IVA cervical cancer.


Files in this item

This item appears in the following Collection(s)

Show simple item record